Searched for
SOTROVIMAB
WHO 'strongly advises against' use of two COVID-19 antibody therapies, says British Medical JournalThe WHO Guideline Development Group of international experts noted that antibody drugs sotrovimab and casirivimab-imdevimab are not recomme...- GSK-Vir therapy works against Omicron sub-variant, data suggestsBased on pseudovirus and extensive pharmacokinetic data, the company said it believed the 500 mg dose of sotrovimab is sufficient to retain...
- How does Merck's COVID-19 pill compare to Pfizer's?Merck in November said its full trial results showed that molnupiravir lowered the chance of hospitalization or death by about 30% in patie...
- Anti-Covid drugs potent against Omicron, antibody therapies less effective: StudyThe lab tests also showed that some antibodies have entirely lost their ability to neutralise Omicron at realistic dosages. "The bottom lin...
- US FDA study warns against certain treatments for Omicron. Details hereWith the continuous rise in Omicron cases of Covid-19, patients are looking at various drug options to relieve some symptoms. US-based infe...
- USFDA revokes emergency use status to two Covid antibody therapies"Because data show these treatments are highly unlikely to be active against the omicron variant, which is circulating at a very high frequ...
- Covid vaccine booster provides effective antibody protection against Omicron: Lancet studyA third dose of the COVID-19 vaccine increases the level of antibodies that can effectively neutralise the Omicron variant of coronavirus, ...
- GSK to increase Covid drug capacity, but no plans for India yetThe company didn't specify any timelines on when the drug will be available in India, or whether it has initiated any discussions with the ...
- Which medicine works best for Covid-19 treatment? WHO answersFor those infected, it is important to know your best treatment options -- the right medicines and drugs that have been effective in reduci...
- Covid cases on the rise, experts call for newer drugs, faster approvalsThe Drug Controller General of India had last week approved Merck and Ridgeback’s antiviral molnupiravir for the treatment of mild-to-moder...
- Omicron variant resistant to antibodies, two vaccine doses: StudyHowever, the study found that a third dose of the Pfizer vaccine, and mixing Pfizer and AstraZeneca preventives may protect well against th...
- India may have to wait longer for Pfizer, GSK's Covid drugsLast month Pfizer had announced an agreement with the UN's Medicines Patent Pool (MPP) for licensing antiviral intellectual property to MPP...
- Scientists identify antibodies that can block Omicron variantScientists have identified antibodies that neutralise Omicron and other variants of coronavirus by targeting areas that remain essentially ...
- J&J, Sinopharm, Sputnik V COVID-19 shots less effective against Omicron -studyVaccines from Moderna, AstraZeneca, Pfizer and partner BioNTech retained activity against Omicron, but the antibody response was greatly re...
- Omicron more transmissible than Delta: UK PM Boris Johnson to ministersJohnson's official Number 10 Downing Street spokesperson told reporters in an account of the Cabinet meeting that Johnson reiterated it was...
- New data shows GSK-Vir drug works against all Omicron mutationsThe data, yet to be published in a peer-reviewed medical journal, shows that the companies' treatment, sotrovimab, is effective against all...
- GSK says antibody drug 'Sotrovimab' works against OmicronUK's Medicines and Healthcare products Regulatory Agency has approved sotrovimab, a Covid-19 treatment which has been developed by GSK and ...
- Pfizer's pill is the latest COVID treatment to show promise. Here are some moreAccording to Pfizer's trial results, Paxlovid could be used as an alternative to in-hospital treatment for preventing disease progression i...
- GSK gears up to bring antibody cocktail drug to India; Zydus ready for trial“We are exploring all options to quickly make this important medicine available for Indian patients,” GSK India spokesperson told ET. Earli...
Load More
